Takeda Oncology presented efficacy and safety data from the phase III PhALLCON trial studying Iclusig (ponatinib) in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia during a virtual American Society of Clinical Oncology’s Plenary Series Program Feb. 15.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.
